What Is ESMO? The European Society for Medical Oncology

The European Society for Medical Oncology, known as ESMO, is a professional organization for cancer specialists founded in 1975 with the goal of advancing medical oncology across Europe and, increasingly, around the world. It publishes widely used treatment guidelines, runs one of the largest annual oncology congresses, sets training standards for cancer doctors, and develops tools that help clinicians, patients, and health authorities evaluate new cancer therapies. If you have ever seen a cancer treatment recommendation labeled “ESMO guidelines” or heard a new drug described by its “ESMO-MCBS score,” the organization behind those references is ESMO.

Origins and Mission

ESMO was established in 1975 to promote the specialty of medical oncology on a pan-European basis, at a time when cancer treatment in many countries was still fragmented across surgery, radiotherapy, and internal medicine without a dedicated specialty for drug-based cancer care.¹ Over the decades the society grew from a primarily Western European network into a global organization. Its membership now includes oncologists, researchers, nurses, and other cancer professionals from well over a hundred countries, though Europe remains its center of gravity.

The society’s core mission covers four areas: clinical practice guidance, scientific research and publication, professional education, and cancer policy advocacy. Each of these branches has produced specific tools and programs that show up in day-to-day oncology around the world, and they are worth understanding individually.

Clinical Practice Guidelines

ESMO’s treatment guidelines are among the most referenced sets of cancer care recommendations outside the United States. They cover the full spectrum from early-stage solid tumors to advanced metastatic disease and blood cancers. The guidelines are built by multidisciplinary panels of European experts who review published clinical trial data, grade the strength of the evidence, and subject their drafts to independent peer review before the ESMO Guidelines Committee endorses them.²

What sets these guidelines apart from a simple list of approved drugs is that they integrate a value framework called the ESMO-MCBS (more on that below) to flag how much real-world benefit a treatment actually delivers. A drug might be approved by regulators, but the ESMO guideline will note whether the improvement it offers is large, modest, or marginal. That additional layer of judgment makes ESMO guidelines especially useful for oncologists working in health systems where resources are limited and choices between therapies have budget implications.

National guideline bodies sometimes benchmark their own recommendations against ESMO’s. A comparative study of Bulgaria’s national breast cancer treatment guideline, for example, used structured methodology to assess its alignment with ESMO, NCCN, and ASCO guidelines on screening, drug therapy, follow-up, and shared decision-making.³ That kind of cross-referencing happens regularly around the world, which is a practical sign of ESMO’s influence on how cancer care standards get set outside the US.

Measuring the Value of New Cancer Drugs

Cancer drugs are expensive and their benefits vary enormously. Some add years of survival; others extend life by weeks while causing serious side effects. ESMO developed a scoring system called the Magnitude of Clinical Benefit Scale (ESMO-MCBS) to put numbers on this difference, giving clinicians and policymakers a standardized way to compare how much good a new treatment does relative to what was available before.

The scale evaluates both curative and non-curative settings. In the curative setting, it looks at outcomes like disease-free survival and overall survival and weighs how large the absolute gains are. In the non-curative (advanced or metastatic) setting, it evaluates how much a drug extends life or slows disease progression and factors in quality-of-life improvements and toxicity. A drug that delivers a big survival advantage with manageable side effects earns a high score; one that shows a tiny statistical edge but comes with harsh toxicity scores much lower.

The scale has evolved over time. Version 1.1 introduced amendments to address issues that surfaced after the original 2015 launch, including adjustments triggered by the rise of immunotherapy and more nuanced handling of certain endpoints.⁴ Version 2.0, published in 2025, went further with thirteen amendments addressing identified shortcomings. Among them: in the curative setting, therapies evaluated on disease-free survival now receive credit for extended time without treatment or disease recurrence even when overall survival data are not yet mature, while small absolute gains in disease-free survival are scored more conservatively than before. Toxicity annotations were expanded to distinguish between short-term and persistent side effects. In advanced disease, the approach to evaluating late differences in survival curves was made more statistically rigorous.⁵

These scores are not just academic. A retrospective study across six countries found that drugs with high ESMO-MCBS scores were more likely to receive positive reimbursement decisions from national health technology assessment agencies, and they reached those decisions faster than drugs with low or average scores.⁶ In other words, ESMO-MCBS scores influence not just clinical practice but whether patients in a given country can access a drug through their public health system.

Precision Medicine and Genomic Testing

Cancer treatment increasingly depends on identifying specific genetic alterations in a tumor and matching them to targeted drugs. ESMO has been active in trying to bring order to a rapidly expanding and sometimes confusing field through two complementary tools: a ranking system for genomic targets and formal recommendations about when to use broad genomic testing.

The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) classifies genomic alterations into tiers based on how strong the evidence is that a matched drug will help the patient. At the top, tier I targets are ready for routine clinical use, meaning there is solid trial evidence that patients with that alteration benefit from a specific therapy. Tier II targets likely define a population that benefits from a targeted drug but need more data. Tier III covers alterations where benefit has been demonstrated in a different tumor type or for a similar molecular target. Tiers IV and V deal with preclinical and combination-targeting evidence, respectively. Tier X means there is currently no evidence the alteration is actionable.⁷

This tiered system matters because genomic testing can turn up dozens or hundreds of mutations in a single tumor. Without a framework for deciding which ones actually warrant a change in treatment, both oncologists and patients can end up overwhelmed or, worse, chasing therapies based on weak evidence. ESCAT gives clinicians a shared vocabulary for discussing which findings are worth acting on.

ESMO also issues recommendations about which cancer types warrant broad genomic sequencing. In 2020, the Precision Medicine Working Group recommended routine multi-gene sequencing of tumor tissue in advanced non-squamous non-small-cell lung cancer, prostate cancer, ovarian cancer, and cholangiocarcinoma (bile duct cancer).⁸ A 2024 update expanded that list to include advanced breast cancer and several rare tumors including gastrointestinal stromal tumors, sarcoma, thyroid cancer, and cancers of unknown primary origin. The updated recommendation also advised sequencing to detect tumor-agnostic alterations in patients with metastatic cancers when matched therapies are available.⁹ “Tumor-agnostic” means the drug targets a specific mutation regardless of where the cancer started, which is a relatively new concept in oncology and one that requires broad testing to uncover.

The Annual Congress

Every autumn, ESMO holds its annual congress, one of the largest gatherings of oncology professionals in the world. The meeting serves as a venue for presenting late-breaking clinical trial results, many of which go on to change treatment standards. Pharmaceutical companies often time their biggest data releases to coincide with the ESMO congress, and the presentations are closely watched by clinicians, investors, and patient advocacy groups alike.

To help practicing oncologists make sense of the flood of data, ESMO-affiliated researchers have published reviews that identify the presentations with the most potential impact on daily practice. After the 2022 congress, for example, a narrative review selected twelve oral presentations judged most likely to shape future treatment, analyzing their methodology, clinical benefit, and whether the findings could realistically be implemented in routine care.¹⁰ That kind of curated filtering is useful in a field where hundreds of abstracts compete for attention at a single meeting.

ESMO also publishes several peer-reviewed journals. Annals of Oncology is its flagship publication and one of the highest-impact oncology journals in the world. ESMO Open covers a broader range of clinical and translational research, and ESMO Real World Data and Digital Oncology is a newer journal focused on real-world evidence and digital health tools. Together, these publications give the society a significant presence in the oncology literature year-round, not just at congress time.

Training Standards for Cancer Doctors

One of ESMO’s less visible but deeply influential roles involves defining what it means to be properly trained as a medical oncologist. Together with the American Society of Clinical Oncology (ASCO), ESMO publishes a Global Curriculum in Medical Oncology, a set of recommendations for what knowledge and competencies a physician should acquire during oncology training to qualify as a specialist.

The curriculum was first published in 2004, updated in 2010, and has continued to evolve.¹¹ The 2023 edition provides detailed recommendations covering the scientific foundations of oncology, tumor biology, staging and treatment modalities, palliative care, communication skills, research methodology, and ethics.¹² The aim is to establish a shared international standard so that an oncologist trained in Portugal and one trained in Japan have comparable foundational knowledge, even though training structures differ widely between countries.

ESMO also runs an examination and certification program. Passing the ESMO exam gives an oncologist a recognized credential that is independent of national certification. In countries where medical oncology is not yet recognized as a distinct specialty or where training pathways vary in quality, that credential can serve as an external benchmark of competence.

Policy Advocacy and Global Health

Beyond clinical guidance, ESMO is active in cancer policy at the international level. The society has a long-standing collaboration with the World Health Organization focused on reducing the global cancer burden, improving access to essential cancer medicines, and aligning regulatory standards across regions.¹³ This collaboration addresses a reality that is easy to overlook from inside wealthy health systems: in many low- and middle-income countries, basic cancer treatments that have been standard of care for decades are still difficult to obtain.

ESMO has also surveyed the availability and affordability of cancer medicines globally, tracking out-of-pocket costs and accessibility gaps. These studies give advocates and governments data they can use to push for policy changes. When ESMO-MCBS scores influence reimbursement decisions, as the Lancet Oncology study described earlier showed, the connection between ESMO’s value framework and actual patient access becomes concrete rather than theoretical.

Burnout, Well-Being, and Gender Equity in Oncology

Oncology is a specialty with high emotional demands, and ESMO has invested in addressing the well-being of the professionals who deliver cancer care. In late 2019, ESMO established a Resilience Task Force to study and support the mental health of oncology healthcare professionals globally.¹⁴

The timing proved significant. When COVID-19 hit, the task force was already in place to survey the pandemic’s impact on oncology professionals. The first wave of their survey, which collected responses from over 1,500 participants across 101 countries, found that about a quarter of respondents were at risk of poor well-being, roughly 38% reported burnout, and two-thirds said their job performance had declined compared with the pre-pandemic period.¹⁵ Those numbers put concrete evidence behind what many in the field sensed anecdotally and gave institutions something to point to when arguing for mental health resources and workload reforms.

Gender equity is another area where ESMO has been vocal. The society’s Women for Oncology Committee has conducted surveys tracking career barriers and workplace culture. A follow-up survey in 2021, with nearly 1,500 respondents, found that lack of leadership development for women and unconscious bias were viewed as more important barriers than they had been in a smaller 2016 survey. Reports of workplace harassment also increased from about 41% in 2016 to roughly 50% in 2021.¹⁴ Whether that increase reflects worsening conditions or greater willingness to report is debatable, but either way the data have kept the conversation active within the oncology community.

Real-World Evidence and Artificial Intelligence

Clinical trials are the gold standard for evaluating cancer treatments, but they involve carefully selected patients in controlled settings. Real-world evidence, drawn from electronic health records, registries, and insurance claims, can reveal how treatments perform in the broader, messier population of actual cancer patients. ESMO has worked to standardize how this type of evidence is reported, publishing a set of 35 recommendations covering every section of a real-world evidence publication, from title and methods to results and discussion.¹⁶ The intent is to make real-world studies more transparent and comparable, reducing the risk that poorly designed analyses get treated as equivalent to rigorous ones.

On the artificial intelligence front, ESMO has begun setting baseline standards for AI-based biomarkers in oncology. AI tools that analyze pathology slides, radiology images, or genomic data to predict treatment response are proliferating fast, but many lack adequate validation. ESMO’s proposed framework, called EBAI (Basic Requirements for AI-based Biomarkers In Oncology), establishes minimum validation requirements organized by the type of biomarker. The simplest class requires concordance studies showing the AI agrees with established methods. More complex classes require analytical validation, high-quality retrospective data, and for the highest tier, prospective clinical trial data showing the AI-guided prediction actually improves treatment outcomes.¹⁷ This is early-stage work, but it reflects ESMO’s pattern of trying to create shared evaluation frameworks before a field becomes too fragmented to standardize.

How ESMO Compares to ASCO and NCCN

If you are based in the United States, you are more likely to encounter guidelines from ASCO (the American Society of Clinical Oncology) or the NCCN (National Comprehensive Cancer Network). ESMO, ASCO, and NCCN all produce cancer treatment guidelines, but their approaches and audiences differ in ways that matter.

NCCN guidelines are algorithm-heavy, providing detailed decision trees that walk clinicians through treatment choices step by step. They update frequently and are the default reference in most American cancer centers. ASCO tends to publish focused guideline statements on specific clinical questions, often synthesizing systematic reviews. ESMO’s guidelines fall somewhere in between, offering structured recommendations with evidence grading while integrating the ESMO-MCBS value assessment that neither ASCO nor NCCN provides in the same way.

The practical difference is that ESMO guidelines are designed with European health systems in mind, where treatment decisions often involve government reimbursement bodies and health technology assessment agencies. The ESMO-MCBS score, by quantifying how much clinical benefit a drug adds, gives those agencies a tool for making coverage decisions. NCCN guidelines, by contrast, are written for a largely insurance-based system where the range of covered therapies tends to be broader but where out-of-pocket costs can be steep in different ways. Neither approach is inherently better; they serve different systems and different decision-making cultures.

ESMO and ASCO collaborate on several fronts despite being separate organizations. The joint Global Curriculum in Medical Oncology is the most visible product of that partnership, but they also co-sponsor educational sessions and share platforms at each other’s conferences. For oncologists working in countries outside both the US and Europe, all three organizations’ guidelines may be consulted, with the final treatment choice shaped by local drug availability and reimbursement conditions.